{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=24", "query": { "intervention": "Irinotecan (Camptosar)", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 921, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T22:26:07.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04340141", "title": "Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Adenosquamous Carcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage I Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2020-10-13", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 441, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340141" }, { "nct_id": "NCT00294931", "title": "Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Small Cell Lung" ], "interventions": [ { "name": "irinotecan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-02", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2010-06-28", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 4, "location_summary": "Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00294931" }, { "nct_id": "NCT03139331", "title": "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Refractory Sarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Years to 30 Years" }, "enrollment_count": 16, "start_date": "2017-06-06", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 3, "location_summary": "Oakland, California • San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139331" }, { "nct_id": "NCT02096354", "title": "A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-05", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 5, "location_summary": "La Jolla, California • Stanford, California • Honolulu, Hawaii + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096354" }, { "nct_id": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Neuroblastoma", "Relapsed Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 24, "start_date": "2023-11-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400603" }, { "nct_id": "NCT00861783", "title": "Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "irinotecan and ON 01910.Na", "type": "DRUG" }, { "name": "oxaliplatin and ON 01910.Na", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-06", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2017-06-23", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861783" }, { "nct_id": "NCT00005951", "title": "Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005951" }, { "nct_id": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-Intestinal Cancer" ], "interventions": [ { "name": "Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2022-07-13", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 6, "location_summary": "Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332002" }, { "nct_id": "NCT00003245", "title": "Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "15 Years to 75 Years" }, "enrollment_count": 50, "start_date": "1998-02-18", "completion_date": "2004-07-30", "has_results": false, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003245" }, { "nct_id": "NCT03883919", "title": "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Serum and plasma blood samples", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-11", "completion_date": "2022-07-02", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-15T22:26:07.811Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03883919" } ] }